Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomark… Read more
Nextage Therapeutics Ltd (MCTC) - Total Assets
Latest total assets as of June 2020: ILA4.90 Million ILA
Based on the latest financial reports, Nextage Therapeutics Ltd (MCTC) holds total assets worth ILA4.90 Million ILA as of June 2020.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nextage Therapeutics Ltd - Total Assets Trend (2002–2019)
This chart illustrates how Nextage Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nextage Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2019)
Nextage Therapeutics Ltd's total assets of ILA4.90 Million consist of 24.7% current assets and 75.3% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 18.0% |
| Accounts Receivable | ILA2.00K | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA65.00K | 1.1% |
| Intangible Assets | ILA847.00K | 14.1% |
| Goodwill | ILA3.61 Million | 60.1% |
Asset Composition Trend (2002–2019)
This chart illustrates how Nextage Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nextage Therapeutics Ltd's current assets represent 24.7% of total assets in 2019, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 18.0% of total assets in 2019, up from 16.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 60.1% of total assets.
Nextage Therapeutics Ltd Competitors by Total Assets
Key competitors of Nextage Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lavipharm S.A
AT:LAVI
|
Greece | €125.48 Million |
|
Medicon Hellas S.A.
AT:MEDIC
|
Greece | €31.81 Million |
|
Tsumura & Co
MU:TSUA
|
Germany | €516.49 Billion |
|
Gibui Holdings Ltd
TA:GIBUI
|
Israel | ILA445.00 Million |
|
Menivim The New REIT Ltd
TA:MNRT
|
Israel | ILA3.73 Billion |
|
Value Capital One Ltd
TA:PLTF
|
Israel | ILA42.86 Million |
|
Aviv Arlon Ltd
TA:AVLN
|
Israel | ILA24.79 Million |
|
Abra Information Technologies
TA:ABRA
|
Israel | ILA645.04 Million |
Nextage Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nextage Therapeutics Ltd generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nextage Therapeutics Ltd is currently not profitable relative to its asset base.
Nextage Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.44 | 1.35 | 0.82 |
| Quick Ratio | 0.44 | 1.35 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-613.00K | ILA 407.00K | ILA -317.00K |
Nextage Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Nextage Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | ILA6.01 Million |
| Market Capitalization | $45.15K USD |
Valuation Analysis
Below Book Valuation: The market values Nextage Therapeutics Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nextage Therapeutics Ltd's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nextage Therapeutics Ltd (2002–2019)
The table below shows the annual total assets of Nextage Therapeutics Ltd from 2002 to 2019.
| Year | Total Assets | Change |
|---|---|---|
| 2019-12-31 | ILA6.01 Million | +9.68% |
| 2018-12-31 | ILA5.48 Million | -55.82% |
| 2017-12-31 | ILA12.39 Million | +8.48% |
| 2016-12-31 | ILA11.43 Million | -13.06% |
| 2015-12-31 | ILA13.14 Million | -22.70% |
| 2014-12-31 | ILA17.00 Million | -42.92% |
| 2013-12-31 | ILA29.78 Million | +29.10% |
| 2012-12-31 | ILA23.07 Million | +4.64% |
| 2011-12-31 | ILA22.05 Million | +38.99% |
| 2010-12-31 | ILA15.86 Million | +80.60% |
| 2009-12-31 | ILA8.78 Million | +38.82% |
| 2008-12-31 | ILA6.33 Million | -49.39% |
| 2003-12-31 | ILA12.50 Million | -27.52% |
| 2002-12-31 | ILA17.25 Million | -- |